Intellia Therapeutics, Inc. (NTLA): Shareholders' Equity
$671.39M
As of 2025-12-31
$727.71M
As of 2026-06-30
-18.4%
3-year compound annual growth
+5.0%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $671.39M | -23.0% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $871.96M | -17.0% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $1.05B | -15.0% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $1.24B | +18.8% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $1.04B | +97.4% | 2024-02-22, Balance as of period end |
| 2020-12-31 | $527.07M | +95.3% | 2023-02-23, Balance as of period end |
| 2019-12-31 | $269.88M | -2.9% | 2023-02-23, Balance as of period end |
| 2018-12-31 | $277.92M | -7.5% | 2021-02-26, Balance as of period end |
| 2017-12-31 | $300.60M | +43.3% | 2020-02-27, Balance as of period end |
| 2016-12-31 | $209.84M | n/m | 2019-02-27, Balance as of period end |
| 2015-12-31 | -$21.20M | n/m | 2018-03-14, Balance as of period end |
| 2014-12-31 | $7.57M | n/a | 2017-03-14, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $671.39M | -23.0% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $68.78M | -16.5% |
| Immucell Corp (ICCC) | 2025-12-31 | $27.06M | -1.7% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | -$6.93M | n/m |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $30.16M | +75.4% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $368.00M | -47.5% |
| Neogen Corp (NEOG) | 2026-05-31 | $2.09B | +1.0% |
| Biomerica Inc (BMRA) | 2026-05-31 | $2.63M | -35.9% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | -$31.46M | n/m |
Compare NTLA, TKNO, ICCC, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗